These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 6852909

  • 21. Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis.
    Nagill R, Mahajan R, Sharma M, Kaur S.
    Parasitol Int; 2009 Dec; 58(4):359-66. PubMed ID: 19638322
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes.
    Scott P, Pearce E, Natovitz P, Sher A.
    J Immunol; 1987 Jul 01; 139(1):221-7. PubMed ID: 3495599
    [Abstract] [Full Text] [Related]

  • 24. Prophylactic immunization against experimental leishmaniasis. V. Mechanism of the anti-protective blocking effect induced by subcutaneous immunization against Leishmania major infection.
    Liew FY, Singleton A, Cillari E, Howard JG.
    J Immunol; 1985 Sep 01; 135(3):2102-7. PubMed ID: 3160786
    [Abstract] [Full Text] [Related]

  • 25. Barley beta-Glucan and Zymosan induce Dectin-1 and Toll-like receptor 2 co-localization and anti-leishmanial immune response in Leishmania donovani-infected BALB/c mice.
    Patidar A, Mahanty T, Raybarman C, Sarode AY, Basak S, Saha B, Bhattacharjee S.
    Scand J Immunol; 2020 Dec 01; 92(6):e12952. PubMed ID: 32748397
    [Abstract] [Full Text] [Related]

  • 26. Studies on cocktails of 31-kDa, 36-kDa and 51-kDa antigens of Leishmania donovani along with saponin against murine visceral leishmaniasis.
    Kaur H, Thakur A, Kaur S.
    Parasite Immunol; 2015 Apr 01; 37(4):192-203. PubMed ID: 25615543
    [Abstract] [Full Text] [Related]

  • 27. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis.
    Das P, Paik D, Naskar K, Chakraborti T.
    Microbes Infect; 2018 Jan 01; 20(1):37-47. PubMed ID: 28970116
    [Abstract] [Full Text] [Related]

  • 28. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL, Holzmuller P, Gonçalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G.
    Vaccine; 2007 May 22; 25(21):4223-34. PubMed ID: 17395339
    [Abstract] [Full Text] [Related]

  • 29. Leishmania donovani phosphoproteins pp41 and pp29 re-establishes host protective immune response in visceral leishmaniasis.
    Das P, Amit A, Singh SK, Chaudhary R, Dikhit MR, Yadav A, Pandey K, Das VN, Sundram S, Das P, Bimal S.
    Parasitol Int; 2015 Feb 22; 64(1):18-25. PubMed ID: 25224164
    [Abstract] [Full Text] [Related]

  • 30. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.
    Stäger S, Smith DF, Kaye PM.
    J Immunol; 2000 Dec 15; 165(12):7064-71. PubMed ID: 11120835
    [Abstract] [Full Text] [Related]

  • 31. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
    Choudhury R, Das P, De T, Chakraborti T.
    Immunobiology; 2013 Jan 15; 218(1):114-26. PubMed ID: 22440312
    [Abstract] [Full Text] [Related]

  • 32. Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes.
    Ali N, Afrin F.
    J Parasitol; 1997 Feb 15; 83(1):70-5. PubMed ID: 9057699
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.
    Aguilar-Be I, da Silva Zardo R, Paraguai de Souza E, Borja-Cabrera GP, Rosado-Vallado M, Mut-Martin M, García-Miss Mdel R, Palatnik de Sousa CB, Dumonteil E.
    Infect Immun; 2005 Feb 15; 73(2):812-9. PubMed ID: 15664920
    [Abstract] [Full Text] [Related]

  • 36. Relationship between delayed hypersensitivity response and acquired cell-mediated immunity in C57BL/6J mice infected with Leishmania donovani.
    Fahey JR, Herman R.
    Infect Immun; 1985 Aug 15; 49(2):447-51. PubMed ID: 4018876
    [Abstract] [Full Text] [Related]

  • 37. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis.
    Rachamim N, Jaffe CL.
    J Immunol; 1993 Mar 15; 150(6):2322-31. PubMed ID: 8450215
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The immunomodulatory effect of yeast glucan on delayed hypersensitivity.
    Pérez HA, Bolívar J, San Blas G.
    J Immunopharmacol; 1984 Mar 15; 6(4):305-21. PubMed ID: 6527008
    [Abstract] [Full Text] [Related]

  • 40. Leishmanial CpG DNA nanovesicles: A propitious prophylactic approach against visceral leishmaniasis.
    Tiwari RK, Chandrakar P, Gupta CL, Sayyed U, Shekh R, Bajpai P.
    Int Immunopharmacol; 2021 Jan 15; 90():107181. PubMed ID: 33249044
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.